Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675135 | 0.88 | PRMT5 (0.47) | PRMT5WDR77SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL30499662 | 0.84 | ALDH1A1 (0.41) | PRMT5WDR77SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL9958767 | 0.84 | CNR1 (0.45) | PRMT5WDR77ALDH1A1POLB | |
| SCHEMBL9959490 | 0.84 | PRMT5 (0.42) | PRMT5WDR77SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL29411937 | 0.84 | CNR1 (0.45) | PRMT5WDR77ALDH1A1POLB | |
| SCHEMBL9959238 | 0.84 | ALDH1A1 (0.41) | PRMT5WDR77SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL9959556 | 0.83 | PRMT5 (0.46) | PRMT5WDR77SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL10153615 | 0.83 | SCN9A (0.54) | SMN1; SMN2ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9958833 | 0.83 | ALDH1A1 (0.42) | PRMT5WDR77SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL29696849 | 0.82 | NPC1 (0.47) | PRMT5WDR77ALDH1A1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012085003-A1 | 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-28 | — | — | WO | claimed |
| US-20250228963-A1 | HYDROGEL PRODRUG FOR TREATMENT | VIKING SCIENTIFIC, INC | 2025-07-17 | — | — | US | disclosed |
| US-20250228962-A1 | HYDROGEL PRODRUG FOR TREATMENT | VIKING SCIENTIFIC, INC. | 2025-07-17 | — | — | US | disclosed |
| CN-119932195-A | Method for detecting cisplatin resistance of bladder cancer based on exosome miRNA markers and application | 沈德鑫 | 2025-05-06 | — | — | CN | disclosed |
| CN-119595757-A | Rapid identification method and monitoring system for fatigue damage stage of asphalt mixture | 长沙理工大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-119492618-A | Rock anisotropy parameter measurement method | 中国石油化工股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-12146140-B2 | T-lymphocyte binding aptamers | AUMMUNE LTD. (IL) | 2024-11-19 | — | — | US | disclosed |
| CN-118817852-A | System for testing frequency characteristic of acoustic emission signal of concrete structure and sensor selection method | 水利部水工金属结构质量检验测试中心 | 2024-10-22 | — | — | CN | disclosed |
| US-12083184-B2 | Hydrogel prodrug for treatment | VIKING SCIENTIFIC, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118408828-A | Rock double-shaft tension test device and rock double-shaft tension test method | 中国地质大学（武汉） | 2024-07-30 | — | — | CN | disclosed |
| CN-115761904-A | Weak supervision video time sequence action positioning method based on multi-head cross-modal attention mechanism | 复旦大学 | 2023-03-07 | — | — | CN | disclosed |
| US-20220354964-A1 | HYDROGEL PRODRUG FOR TREATMENT | VIKING SCIENTIFIC, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220354965-A1 | HYDROGEL PRODRUG FOR TREATMENT | VIKING SCIENTIFIC, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220186223-A1 | T-LYMPHOCYTE BINDING APTAMERS | AUMMUNE LTD. (IL) | 2022-06-16 | — | — | US | disclosed |
| WO-2022118077-A2 | T-LYMPHOCYTE BINDING APTAMERS | AUMMUNE LTD. (IL) | 2022-06-09 | — | — | WO | disclosed |
| US-11331395-B2 | Hydrogel prodrug for treatment | VIKING SCIENTIFIC, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11273226-B2 | Hydrogel prodrug for treatment | VIKING SCIENTIFIC, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20190070165-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | SAINT LOUIS UNIVERSITY (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017161133-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | SAINT LOUIS UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2012085003-A1 | 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070165-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | HCCS, HAVCR2, HDGF | PRMT5 320/4885WDR77 1828/4885SMN1; SMN2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.